MACO (Cleaning Acceptance Limit)
Part 111 requires equipment to be cleaned and the cleaning documented; the numeric Maximum Allowable Carryover limit that decides whether a swab result passes is an industry calculation layered on top, not a specific figure the regulation names.

On this page · 8 sections
- 1What Part 111 actually requires on cleaning
- 2Why firms adopt a numeric carryover limit at all
- 3Common MACO calculation approaches, and what each assumes
- 4Swab and rinse sampling against the limit
- 5Allergen carryover is a separate question from potency-based MACO
- 6Worst-case product and equipment-train selection
- 7Records that tie the calculation to the equipment log
- 8Pitfalls that turn a documented limit into an inspection finding
How does MACO (Cleaning Acceptance Limit) apply to your shop floor?
Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.
01What Part 111 actually requires on cleaning
21 CFR 111.27(a) requires that equipment and utensils used in dietary supplement manufacturing be of appropriate design, construction and workmanship so they can be adequately cleaned and properly maintained, and so their use will not contaminate components or dietary supplements with lubricants, fuel, coolants, metal or glass fragments, filth, or any other contaminant. Section 111.27(d) then states the operating obligation directly: a firm "must maintain, clean, and sanitize, as necessary, all equipment, utensils, and any other contact surfaces used to manufacture, package, label, or hold components or dietary supplements," taking equipment apart as necessary for thorough cleaning, keeping dry-process contact surfaces dry and sanitary, and cleaning and sanitizing wet-process contact surfaces before use and after any interruption that could have introduced contamination.
111.27(d) also requires cleaning of non-contact surfaces as frequently as necessary to prevent contaminating components or supplements, specifies that cleaning compounds and sanitizing agents must be adequate for their intended use and safe under their conditions of use, and requires cleaned and sanitized portable equipment to be stored so it stays protected from contamination. Nowhere in 111.27 does the text name a numeric residue limit, a swab recovery percentage, a required analytical method, or a required number of qualification runs; the regulation describes an outcome — adequately clean, adequately maintained equipment that does not contaminate the next product — and leaves the firm to establish and document how it meets that outcome.
21 CFR 111.35(b) is the records half of the same subpart. It requires written procedures for maintaining, cleaning and sanitizing equipment, utensils and other contact surfaces; documentation in individual equipment logs of the date equipment was used, maintained, cleaned and sanitized (unless that documentation is kept with the batch record); and documentation of the controls a firm uses to ensure equipment functions in accordance with its intended use. That last clause is where a firm's cleaning acceptance criteria — however it derives them — become a recorded requirement: if a MACO limit, a visual-clean check, or an analytical swab result is part of how the firm demonstrates equipment functions as intended for the next product, 111.35(b)(6) expects that control to be documented.
02Why firms adopt a numeric carryover limit at all
Shared equipment is common in supplement manufacturing: the same blender, tablet press, encapsulator or mixing tank is often used for multiple formulas in sequence. A cleaning step that leaves some residue of the previous product behind creates carryover into the next lot. 'Adequately cleaned' in 111.27(a) and 'clean, and sanitize, as necessary' in 111.27(d) are outcome statements; a firm still has to decide how much residual carryover is acceptable before the equipment is considered clean enough to release for the next product, and how it will verify that the actual residue is below that line.
The practice many supplement manufacturers borrow for that decision is Maximum Allowable Carryover (MACO), sometimes written MAC: a calculated residue limit, usually expressed per swabbed surface area or per analyzed rinse volume, that is set low enough that even a worst-case carryover into the smallest likely next batch would not create a meaningful dose of the previous product's active or allergenic material. MACO is not a dietary-supplement-specific concept — it originates in pharmaceutical cleaning validation, where cross-contamination between actives with pharmacological effect is a direct patient-safety question — and firms that apply it to supplements are adapting that framework rather than following a Part 111 mandate.
A firm is free to use a different, equally documented approach — for example a validated visual-clean standard alone, where process knowledge supports that visible absence of residue reliably predicts an acceptable analytical result — provided the rationale and the verification data exist to support it under 111.35(b)(6). What 111.35 does not accept is an undocumented assumption that equipment is clean because it looks clean, with no rationale on file for why that is considered sufficient for the formulas run on that equipment.
03Common MACO calculation approaches, and what each assumes
None of the approaches below is mandated by 21 CFR 111; they are described here as the calculation methods supplement and pharmaceutical manufacturers commonly apply when they choose to set a quantitative cleaning acceptance limit.
Health-based exposure limits (HBEL/PDE)
The EMA's 2014 Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012) describes deriving a Permitted Daily Exposure (PDE) from toxicological or pharmacological data — a no-observed-adverse-effect level or similar point of departure, adjusted by justified safety factors for interspecies and intraspecies variability, exposure duration, severity of effect and the quality of the underlying data — and states that the PDE should be determined by a person with appropriate training and experience, with the calculation and its rationale documented. The guideline was adopted for the manufacture of medicinal products in shared facilities and took effect 1 June 2015; it is not a dietary-supplement regulation. Firms that import the HBEL/PDE method into a supplement cleaning program are applying a pharmaceutical risk-assessment method to active botanical, vitamin or mineral ingredients that typically lack the clinical and nonclinical toxicology dataset a PDE calculation normally draws on, which is a real limitation worth naming before claiming the method as the basis for a limit.
Dose-based (fraction-of-minimum-dose) limits
An older convention, still used as a screening calculation, sets the carryover limit as a small fraction — commonly one-thousandth — of the minimum therapeutic or labeled daily dose of the previous product, scaled by the batch size of the next product and the shared surface area. This method needs only the previous product's label dose and the next product's batch size, which makes it easy to calculate, but it does not reflect the toxicological potency of the specific ingredient and can be either overly conservative or insufficiently protective depending on the ingredient involved.
The 10 ppm convention
A simple fixed criterion sets the acceptance limit at no more than 10 ppm (10 mg of the previous product's residue per kg of the next product), independent of either product's toxicology or dose. It is straightforward to apply and communicate but, like the dose-based approach, is a generic convention rather than an ingredient-specific or health-based calculation.
Visually clean
A visual examination — no residue, film, discoloration or foreign material visible on inspected surfaces under defined lighting — is a baseline check applied in essentially every cleaning verification, including the acceptance criteria named directly in Part 111's text for general cleanliness. On its own, visual inspection cannot detect residue below the human visual detection threshold, which commonly runs from roughly 1 to 4 micrograms per square centimeter depending on the residue, surface and lighting conditions; for that reason, visually clean is typically used alongside a quantitative limit for the lower-threshold compounds, and as the sole criterion only where a firm has data showing visual clean reliably corresponds to an acceptable analytical result for that specific soil and surface.
Multiple of these approaches are often run in parallel: the lowest (most conservative) calculated limit across the HBEL/PDE, dose-based and 10 ppm methods is typically selected as the acceptance criterion, with visually clean applied as an additional pass/fail gate before any sample is even taken. Whichever combination a firm selects, the method, data sources, assumptions and resulting number belong in a documented risk assessment that 111.35(b)(6) records can point back to.
04Swab and rinse sampling against the limit
A MACO figure is only meaningful if it can be compared to an actual measured result, which is where sampling method matters. Swab sampling wipes a defined surface area — commonly a template of 25 to 100 cm² — with a solvent-wetted swab, which is then extracted and analyzed; it directly samples a specific location and is well suited to surfaces that are accessible and where the hardest-to-clean spots (seams, corners, gaskets) can be targeted deliberately. Rinse sampling collects the final rinse solvent passed over equipment, typically used for surfaces that cannot be reached directly with a swab, such as the interior of long pipe runs or fully assembled equipment trains, and gives an average result across the whole rinsed surface rather than a worst-case spot result.
Each sampling method has a recovery factor — the fraction of residue actually present on a surface that the method and analytical procedure successfully detect — that should be established experimentally for the specific residue, surface material and sampling technique, and then applied to correct the measured result (or conservatively, used to tighten the acceptance limit) before comparing against MACO. A swab or rinse program that has not demonstrated its own recovery rate cannot establish with confidence that a passing analytical result actually reflects a surface below the calculated limit.
Analytical methods used against swab or rinse samples range from total organic carbon (TOC), a non-specific but sensitive screen for any carbon-bearing residue, to specific chromatographic assays (HPLC, LC-MS) for a named active or marker compound, selected based on what the MACO limit was calculated for and how low the method's limit of detection or quantification needs to be relative to that limit.
05Allergen carryover is a separate question from potency-based MACO
A MACO limit calculated from toxicology, dose or a fixed ppm convention is built to answer whether carryover of the previous product's active ingredient could meaningfully affect the next product's safety or label claim. It does not answer whether trace carryover of a major food allergen — milk, egg, peanut, tree nuts, wheat, soy, fish, shellfish, or sesame under the allergens named in the Federal Food, Drug, and Cosmetic Act as amended by FASTER — could trigger a reaction in a sensitized consumer, because allergic response thresholds for sensitized individuals can be far lower than a toxicology-derived PDE would suggest, and allergen risk is about sensitization, not dose-proportional toxicity.
Where shared equipment runs both an allergen-containing formula and an allergen-free formula, the cleaning program commonly applies a dedicated allergen-specific verification — frequently a lateral-flow or ELISA-based allergen test kit applied to swab samples — in addition to, not instead of, whatever MACO limit applies to the active ingredients involved. A visually-clean or active-ingredient MACO pass does not by itself demonstrate an allergen-clean surface, and a firm's own labeling decisions (including any precautionary allergen statement) should reflect what the allergen verification actually showed rather than being inferred from the unrelated active-ingredient cleaning result.
Because Part 111 does not separately name allergen-cleaning verification, a firm's rationale for its allergen control approach — what it tests for, how often, and what action a positive result triggers — is itself part of the documented controls that 111.35(b)(6) expects on file to show equipment functions as intended for the formulas run on it.
06Worst-case product and equipment-train selection
Because validating every possible product-to-product transition on shared equipment is rarely practical, firms commonly group equipment into trains with comparable design and surface area, and group products by formula family, then select a worst-case combination to validate: typically the hardest-to-clean product (by solubility, viscosity or known residue tenacity) paired with the lowest calculated MACO (the most potent or lowest-dose next product sharing that equipment). A cleaning procedure validated against that worst-case pairing is then treated as covering the less demanding combinations within the same product and equipment grouping, provided the grouping rationale is documented and periodically reassessed as new products are added.
Equipment design itself feeds back into this grouping decision under 111.27(a) and 111.27(d): equipment with smooth, accessible, correctly bonded surfaces that can be adequately cleaned and, where necessary, taken apart for thorough cleaning is what makes a worst-case validation meaningful across a product family, whereas equipment with inaccessible geometry may need to be validated, or excluded from shared use, individually.
07Records that tie the calculation to the equipment log
111.35(b)(2) requires documentation in individual equipment logs of the date of use, maintenance, cleaning and sanitizing of equipment (or equivalent documentation kept with the batch record), and 111.35(b)(1)(iii) requires written procedures for that maintaining, cleaning and sanitizing activity. A cleaning program built around a MACO limit adds several records layers on top of those baseline requirements: the risk assessment and calculation behind the chosen MACO value and the method (HBEL/PDE, dose-based, 10 ppm, or a documented combination), the sampling plan naming swab or rinse locations and the rationale for worst-case site selection, the recovery-factor study supporting the sampling and analytical method, the analytical results for each cleaning verification compared against the limit, and — where applicable — the separate allergen verification result and action taken on any positive.
- Written cleaning and sanitizing procedure (111.35(b)(1)(iii))
- Individual equipment log or batch-record entry recording date of use, cleaning and sanitizing (111.35(b)(2))
- MACO calculation and the risk assessment or data behind it (supports 111.35(b)(6) 'documentation of the controls')
- Sampling plan: swab or rinse locations, worst-case rationale, recovery-factor data
- Analytical results for each cleaning verification, compared against the acceptance limit
- Allergen verification results and any resulting labeling decision, where shared equipment runs allergen-containing formulas
08Pitfalls that turn a documented limit into an inspection finding
A quoted 10 ppm, 1/1000-dose, or 'visually clean' criterion with no written rationale tying it to the specific products and equipment involved reads, to an inspector, as an assumption rather than a control — 111.35(b)(6) expects the documentation to show how the firm knows the control is adequate, not just that a number exists. Similarly, a sampling and analytical method applied without an established recovery factor leaves open the question of whether a passing result reflects a genuinely clean surface or simply a method that under-recovers residue.
Treating an active-ingredient MACO pass as evidence that allergen carryover is also controlled, without separate allergen-specific verification, is a common gap given how differently allergen risk and toxicological dose-response behave. And a worst-case product or equipment grouping that is not revisited when a new formula, ingredient, or equipment configuration is introduced can quietly stop covering what it was originally validated to cover, which is why periodic review of the grouping and the underlying MACO calculations — not just periodic re-swabbing — belongs in a cleaning program's revalidation triggers.
Frequently asked questions
Q.Does 21 CFR 111 require a MACO or PDE calculation?+
No. Part 111 requires equipment to be adequately cleaned (111.27) and the cleaning and the controls used to confirm equipment functions as intended to be documented (111.35(b)(2) and (b)(6)). MACO, PDE/HBEL, the 10 ppm convention, and dose-based limits are industry calculation methods, largely adapted from pharmaceutical cleaning validation and the EMA's HBEL guideline, that firms use to give those requirements a quantitative, defensible basis — they are not named or mandated in the regulation's text.
Q.Is 'visually clean' enough on its own?+
Only where a firm has data showing that visual inspection reliably predicts an acceptable analytical result for the specific residue and surface involved, because visual detection has a threshold (commonly in the low micrograms-per-square-centimeter range) below which residue can be present but not visible. Most programs use visually clean as a baseline gate alongside a quantitative swab or rinse limit rather than as the sole criterion.
Q.Does a MACO limit also control allergen carryover?+
Not automatically. MACO is typically calculated from an active ingredient's dose or toxicology, while allergen risk depends on sensitization thresholds that can be much lower and are not proportional to the same calculation. Shared equipment running allergen-containing and allergen-free formulas commonly needs a separate, allergen-specific verification (such as a lateral-flow or ELISA swab test) in addition to the active-ingredient MACO check.
Q.What is the difference between swab and rinse sampling?+
Swab sampling wipes a defined surface area directly and can target known hard-to-clean spots, giving a worst-case spot result; rinse sampling analyzes the final rinse solvent and gives an average result across the whole rinsed surface, which is useful for geometry a swab cannot physically reach, such as closed pipework.
Q.Where does the EMA HBEL guideline fit for a dietary supplement manufacturer?+
It is a pharmaceutical guideline (EMA/CHMP/CVMP/SWP/169430/2012, effective 1 June 2015) describing how to derive a Permitted Daily Exposure from toxicological data for medicinal products made in shared facilities. Some supplement manufacturers adapt its PDE methodology for cleaning acceptance limits, but it is not a dietary-supplement regulation, and many botanical or nutrient ingredients lack the toxicological dataset the method assumes — a limitation worth documenting if the method is used.
Q.What records does an inspector expect to see for a MACO-based cleaning program?+
The written cleaning procedure, the individual equipment log or batch-record entry showing date of cleaning (111.35(b)(2)), the risk assessment and calculation behind the chosen limit, the sampling plan and recovery-factor data, the analytical results compared against the limit, and documentation of the controls used to confirm the equipment functions as intended (111.35(b)(6)).
Primary sources
- 21 CFR 111.27 — Equipment and utensils (eCFR) — reviewed 9 Oct 2026
- 21 CFR 111.35 — Records required under subpart D (eCFR) — reviewed 9 Oct 2026
- EMA/CHMP/CVMP/SWP/169430/2012 — Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (20 Nov 2014) — reviewed 9 Oct 2026
- EMA/CHMP/CVMP/SWP/246844/2018 — Questions and answers on implementation of risk-based prevention of cross-contamination and the HBEL guideline — reviewed 9 Oct 2026
Further reading
- Cleaning Validation MACThe pharmaceutical-side view of MAC, HBEL and PDE across shared drug-manufacturing equipment.
- Cleaning ValidationThe broader lifecycle view: risk assessment, qualification runs, monitoring and periodic review.
- Control point monitoring logA working structure for recording the controls used to confirm equipment functions as intended.
Want to see how MACO (Cleaning Acceptance Limit) could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.
